Alnylam Pharmaceuticals, Inc.  

Cambridge,  MA 
United States
  • Booth: 7085

Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. RNAi therapeutics represent a powerful, clinically-validated approach for the treatment of a wide range of debilitating diseases.